Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib plus electrochemotherapy for BRAF V600-mutant in-transit melanoma metastases
2015-004960-12Phase 2Completed
- Sponsor
- Intergruppo Melanoma Italiano
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib, bleomycin and cisplatin in melanoma, sponsored by Intergruppo Melanoma Italiano. Primary endpoint: Progression-free survival. Started Sep 2021; status: completed.
02
Drugs
vemurafenibbleomycincisplatin
03
Conditions
melanoma
Beyond the preview
Go deeper on 2015-004960-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004960-12.